<?xml version="1.0" encoding="UTF-8"?>
<p>With Having a considerable number of people worldwide infected with COVID-19, scientists have identified a number of cases of broad-spectrum antiviral agents (BSAAs) that could serve as potential candidates for the treatment of the viral diseases (Andersen et al., 
 <xref rid="CIT0005" ref-type="bibr">2020</xref>; Ianevski et al., 
 <xref rid="CIT0032" ref-type="bibr">2018</xref>). Indeed, re-purposing of current approved anti-viral drugs could be a solution to treat new viral infections (Guo, 
 <xref rid="CIT0027" ref-type="bibr">2020</xref>; Kouznetsova et al., 
 <xref rid="CIT0039" ref-type="bibr">2014</xref>; Mercorelli et al., 
 <xref rid="CIT0048" ref-type="bibr">2018</xref>; Xu et al., 
 <xref rid="CIT0076" ref-type="bibr">2016</xref>).
</p>
